title: Demonstration of functional alpha4-containing nicotinic receptors in the medial habenula.
abstract: The medial habenula (MHb) exhibits exceptionally high levels of nicotinic acetylcholine receptors (nAChRs), but it remains unclear whether all expressed nAChR subunit mRNAs are translated to form functional receptors. In particular alpha4 subunits have not been reported to have any functional role, despite strong alpha4 mRNA expression in the ventrolateral MHb. We studied a strain of knock-in mice expressing fluorescent alpha4* nAChRs (alpha4YFP), as well as a knock-in strain expressing hypersensitive alpha4* nAChRs (alpha4L9'A). In alpha4YFP mice, there was strong fluorescence in the ventrolateral MHb. In hypersensitive alpha4L9'A mice, injections of a low dose of nicotine (0.1 mg/kg) led to strong c-fos expression in only the ventrolateral region of the MHb, but not in the MHb of wild-type (WT) mice. In MHb slice recordings, ventrolateral neurons from alpha4L9'A mice, but not from WT mice, responded robustly to nicotine (1 microM). Neurons in the medial aspect of the MHb had >10-fold smaller responses. Thus alpha4* nAChRs contribute to the selective activation of a subset of MHb neurons. Subunit composition analysis based on gain-of-function knock-in mice provides a useful experimental paradigm.
authors.affiliation: Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.
authors.forename: Carlos
authors.initials: C
authors.lastname: Fonck
authors.forename: Raad
authors.initials: R
authors.lastname: Nashmi
authors.forename: Ramiro
authors.initials: R
authors.lastname: Salas
authors.forename: Chunyi
authors.initials: C
authors.lastname: Zhou
authors.forename: Qi
authors.initials: Q
authors.lastname: Huang
authors.forename: Mariella
authors.initials: M
authors.lastname: De Biasi
authors.forename: Robin A J
authors.initials: RA
authors.lastname: Lester
authors.forename: Henry A
authors.initials: HA
authors.lastname: Lester
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D019262:Habenula / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D066298:In Vitro Techniques; D008164:Luminescent Proteins / Q000235:genetics; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009538:Nicotine / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D011485:Protein Binding / Q000187:drug effects; D021122:Protein Subunits / Q000235:genetics / Q000378:metabolism*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000378:metabolism*
chemical_list: D008164:Luminescent Proteins; D021122:Protein Subunits; D016760:Proto-Oncogene Proteins c-fos; D012333:RNA, Messenger; D011978:Receptors, Nicotinic; D009538:Nicotine
references.citation: J Neurosci. 2004 Nov 10;24(45):10035-9
references.pmid: 15537871
references.citation: J Neurosci. 2002 Apr 1;22(7):2522-9
references.pmid: 11923417
references.citation: J Neurosci. 2008 Jan 9;28(2):519-28
references.pmid: 18184794
references.citation: J Neurosci. 2003 Jul 16;23(15):6255-63
references.pmid: 12867510
references.citation: J Neurosci. 2003 Apr 1;23(7):2582-90
references.pmid: 12684443
references.citation: Nat Genet. 1995 May;10(1):117-8
references.pmid: 7647781
references.citation: J Neurosci. 2005 Dec 7;25(49):11396-411
references.pmid: 16339034
references.citation: Nature. 1995 Mar 2;374(6517):65-7
references.pmid: 7870173
references.citation: J Neurochem. 2002 Aug;82(3):468-81
references.pmid: 12153472
references.citation: Brain Res Bull. 1985 Jan;14(1):63-83
references.pmid: 2580607
references.citation: Neuropharmacology. 2000 Oct;39(13):2591-603
references.pmid: 11044729
references.citation: Eur J Pharmacol. 2006 May 10;537(1-3):94-8
references.pmid: 16626688
references.citation: Synapse. 2007 Jul;61(7):547-60
references.pmid: 17447255
references.citation: J Pharmacol Exp Ther. 1998 Apr;285(1):377-86
references.pmid: 9536034
references.citation: Curr Opin Pharmacol. 2005 Jun;5(3):280-92
references.pmid: 15907916
references.citation: Biochem Pharmacol. 2007 Oct 15;74(8):1092-101
references.pmid: 17662959
references.citation: J Neurosci. 1990 Jan;10(1):169-75
references.pmid: 2299390
references.citation: J Comp Neurol. 1989 Jun 8;284(2):314-35
references.pmid: 2754038
references.citation: Int Rev Neurobiol. 1986;28:157-82
references.pmid: 2433243
references.citation: Biochem Pharmacol. 2007 Oct 15;74(8):1102-11
references.pmid: 17597586
references.citation: Science. 2004 Nov 5;306(5698):1029-32
references.pmid: 15528443
references.citation: Mol Pharmacol. 2004 Jun;65(6):1333-5
references.pmid: 15155826
references.citation: J Neurosci. 2003 Dec 17;23(37):11554-67
references.pmid: 14684858
references.citation: Nature. 2005 Jul 7;436(7047):103-7
references.pmid: 16001069
references.citation: J Comp Neurol. 1981 Feb 20;196(2):253-70
references.pmid: 7217357
references.citation: Pflugers Arch. 1994 Nov;429(1):27-43
references.pmid: 7708479
references.citation: J Neurosci. 2007 Aug 1;27(31):8202-18
references.pmid: 17670967
references.citation: Neuropharmacology. 1999 Jun;38(6):769-83
references.pmid: 10465681
references.citation: Neurosci Biobehav Rev. 2007;31(5):658-72
references.pmid: 17379307
references.citation: Trends Pharmacol Sci. 2000 Jun;21(6):211-7
references.pmid: 10838608
references.citation: J Physiol. 1995 Apr 1;484 ( Pt 1):87-105
references.pmid: 7541465
references.citation: J Pharmacol Exp Ther. 1996 Jul;278(1):361-9
references.pmid: 8764371
references.citation: Pharmacol Ther. 2001 Nov-Dec;92(2-3):89-108
references.pmid: 11916531
references.citation: J Neurosci. 1992 Jul;12(7):2765-84
references.pmid: 1613557
references.citation: Curr Opin Neurobiol. 1992 Jun;2(3):254-62
references.pmid: 1643408
references.citation: Physiol Genomics. 2007 Nov 14;31(3):422-8
references.pmid: 17712039